Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ER Visits Drop More Than 50% After Infant Cough/Cold Product Withdrawal

This article was originally published in The Tan Sheet

Executive Summary

Manufacturers should improve packaging of OTC pediatric cough/cold medicines and educate consumers about the risk of unsupervised ingestion to reduce further the number of children who need emergency treatment due to the products, researchers and the Consumer Healthcare Products Association say.

You may also be interested in...



Warnings Not To Give Young Children Cough/Cold OTCs Still Go Unheeded

Four in 10 parents said they administered OTC cough and cold products to children younger than 4 years even though labeling says not to use in this age group, according to a national poll. The finding suggests more education is necessary to reduce confusion and noncompliance.

Warnings Not To Give Young Children Cough/Cold OTCs Still Go Unheeded

Four in 10 parents said they administered OTC cough and cold products to children younger than 4 years even though labeling says not to use in this age group, according to a national poll. The finding suggests more education is necessary to reduce confusion and noncompliance.

Acetaminophen Awareness Coalition Prepares To Launch Education Campaign

Consumer health advocates, trade groups and FDA representatives are working together to raise awareness of safe acetaminophen use and to address an advisory committee's concerns about the painkiller.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS104701

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel